November 5, 2014 | The Israeli pharmaceutical company Teva and Active Biotech will expand the Laquinimod clinical development program into Phase II trials. The trials will evaluate the ability of the Laquinimod drug to treat primary progressive multiple sclerosis (PPMS) as well as Huntington’s disease. This would be the first treatment for both PPMS and Huntington’s disease beyond symptom management. The study, called ARPEGGIO, will evaluate the efficacy, safety and tolerability of the Laquinimod drug in patients with PPMS, and the LEGATO-HD trial will test the efficacy and safety of the drug use on individuals with Huntington’s disease. Teva Pharmaceutical Industries was founded in 1901 by Eli Hurvitz.